Today the Food and Drug Administration (FDA) approved a new formulation of a once-daily nonsteroidal anti-inflammatory drug (NSAID) for the treatment of postoperative pain and inflammation in patients ...

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...

In October, ISTA reported statistically significant Phase 3 results for its product candidate, PROLENSA™ (bromfenac ophthalmic solution), which incorporates this proprietary formulation of bromfenac.

ISTA Plans to File PROLENSA New Drug Application in First Quarter 2012 PROLENSA's Formulation Covered by Pending Patent Applications IRVINE, CA, Oct 13, 2011 (MARKETWIRE via COMTEX) -- ISTA ...

Bromfenac ophthalmic solution is a nonsteroidal anti-inflammatory drug indicated for postoperative inflammation in patients who have undergone cataract surgery. Alembic is releasing bromfenac ...

New Once-Daily NSAID Indicated for Treatment of Postoperative Inflammation and Reduction of Ocular Pain Following Cataract Surgery PROLENSA provides powerful and rapid resolution of inflammation and ...

Global pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration (FDA) approved bromfenac ophthalmic solution, 0.07%. Lupin is the exclusive ...

PROLENSA (bromfenac) ophthalmic solution The FDA has approved Bausch & Lomb's New Drug Application for Prolensa ophthalmic solution, which treats post-operative inflammation and reduces ocular pain in ...

today announced that the United States Patent and Trademark Office has issued Patent No. 8,129,431 with claims covering PROLENSA™ (bromfenac ophthalmic solution), ISTA's once-daily topical ...

Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration approved Bausch + Lomb’s new drug application for bromfenac ophthalmic ...